CATABASIS PHARMACEUTICALS IN's ticker is and the CUSIP is 14875P206. A total of 55 filers reported holding CATABASIS PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 0.09 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $130,000 | -9.7% | 61,444 | +23.4% | 0.00% | – |
| Q1 2021 | $144,000 | +14.3% | 49,798 | -15.3% | 0.00% | – |
| Q4 2020 | $126,000 | -92.2% | 58,827 | -77.5% | 0.00% | -100.0% |
| Q3 2020 | $1,617,000 | -1.5% | 261,221 | +2.4% | 0.00% | 0.0% |
| Q2 2020 | $1,641,000 | +60.7% | 255,167 | +3.7% | 0.00% | 0.0% |
| Q1 2020 | $1,021,000 | -26.9% | 245,974 | +4.1% | 0.00% | 0.0% |
| Q4 2019 | $1,397,000 | +14.9% | 236,374 | +4.9% | 0.00% | – |
| Q3 2019 | $1,216,000 | -31.1% | 225,261 | +3.0% | 0.00% | -100.0% |
| Q2 2019 | $1,765,000 | +50.3% | 218,651 | +47.5% | 0.00% | – |
| Q1 2019 | $1,174,000 | – | 148,213 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Soleus Capital Management, L.P. | 775,000 | $2,240,000 | 0.40% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,294,000 | $3,740,000 | 0.29% |
| ArchPoint Investors | 162,826 | $471,000 | 0.13% |
| Ikarian Capital, LLC | 852,998 | $2,464,000 | 0.08% |
| Samsara BioCapital, LLC | 150,000 | $434,000 | 0.08% |
| Perceptive Advisors | 1,933,551 | $5,588,000 | 0.07% |
| Fairmount Funds Management LLC | 53,166 | $154,000 | 0.06% |
| Alyeska Investment Group, L.P. | 1,124,623 | $3,250,000 | 0.04% |
| Alyeska Investment Group, L.P. | 731,303 | $2,113,000 | 0.03% |
| Corient Capital Partners, LLC | 103,523 | $299,000 | 0.03% |